Moderna Halts New Vaccine Trial Investments Amid US Policy Opposition
核心洞察
Moderna CEO Stéphane Bancel announced the company will not invest in new late-stage vaccine trials due to growing opposition to immunizations from US officials.
The decision stems from regulatory delays and lack of support from health authorities under HHS Secretary Robert F. Kennedy Jr., making potential market size "much smaller."
Moderna is seeking outside funding for late-stage trials of vaccines targeting dormant viruses like Epstein-Barr virus (搜索) and herpes simplex virus (搜索).
Moderna will not invest in new late-stage vaccine trials due to mounting opposition to immunizations from US officials, CEO Stéphane Bancel announced during an interview with Bloomberg TV at the World Economic Forum in Davos, Switzerland. The decision reflects the challenging regulatory environment facing vaccine manufacturers under the current administration.
"You cannot make a return on investment if you don't have access to the US market," Bancel stated, explaining that regulatory delays and diminished support from health authorities have significantly reduced the potential market size. Moderna's stock jumped 10.16% in morning trading following the announcement.
Policy Changes Impact Market Access
Under Health and Human Services (搜索) Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, US vaccination policy has undergone rapid changes. The administration has dropped recommendations for COVID-19 (搜索) shots for pregnant women and children, directed states to limit their vaccine mandates, and cut funding for mRNA-based vaccine research.
These policy shifts have created additional obstacles for Moderna, which was already grappling with a post-pandemic decline in its COVID business. Bancel expressed disappointment with the current trajectory, noting, "It's sad for us to see that vaccines that have been proven for decades helping people around the world are not recommended anymore."
Strategic Pivot and Funding Challenges
Moderna is attempting to transition from a company largely focused on COVID shots to one that develops personalized cancer treatments. As part of this strategic shift, the company has indicated it is seeking outside funding to conduct late-stage trials of vaccines targeting viruses that can remain dormant and undetected in the body after infection.
The company's pipeline includes vaccines against Epstein-Barr virus (搜索) and herpes simplex virus (搜索), representing potential new therapeutic areas beyond COVID-19 (搜索). However, the current regulatory climate has complicated investment decisions for these programs.
Industry-Wide Concerns
Bancel's comments represent some of his strongest statements yet regarding the difficulties vaccine manufacturers face under the Trump administration. He joins other pharmaceutical executives who have begun voicing frustrations with the government's approach to immunizations, highlighting broader industry concerns about the changing regulatory landscape for vaccine development and approval.